BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, February 2, 2026
Home » Authors » John Fox

John Fox

Articles

ARTICLES

ERB found to play key role in neural stem cell differentiation

Nov. 22, 2017
By John Fox
Estrogen receptor beta (ER-beta) is an important factor that should be considered in the design of new stem cell-based regenerative therapies for neurodegenerative conditions, a new Swedish-American collaborative study has concluded.
Read More

IL-11 identified as therapeutic target for cardiovascular fibrosis

Nov. 20, 2017
By John Fox

IL-11 identified as therapeutic target for cardiovascular fibrosis

Nov. 17, 2017
By John Fox
Researchers at Duke-National University of Singapore (Duke-NUS) Medical School have discovered for the first time that interleukin-11 (IL-11) may be an important therapeutic target for cardiovascular (CV) fibrotic diseases, including heart and renal failure, they reported in the Nov. 13, 2017, edition of Nature.
Read More

Axon assemblies pave way for drug discovery

Nov. 16, 2017
By John Fox

Axon assemblies pave way for drug discovery

Nov. 15, 2017
By John Fox
The creation of a new microdevice that allows generation of three-dimensional (3-D) axonal structures from human stem cell-derived neurons should facilitate future studies on axon development and allow drug screening for diseases including amyotrophic lateral sclerosis (ALS), a new study has found.
Read More

Axon assemblies pave way for drug discovery

Nov. 13, 2017
By John Fox
The creation of a new microdevice that allows generation of three-dimensional (3-D) axonal structures from human stem cell-derived neurons should facilitate future studies on axon development and allow drug screening for diseases including amyotrophic lateral sclerosis (ALS), a new study has found.
Read More

Molecular map may hold key to new cancer treatments

Nov. 9, 2017
By John Fox

Molecular map may hold key to new cancer treatments

Nov. 8, 2017
By John Fox
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Read More

Molecular map may hold key to new cancer treatments

Nov. 7, 2017
By John Fox
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Read More

Erythropoietin said to induce antiangiogenic drug resistance

Nov. 3, 2017
By John Fox
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing